Update: 14 October 2019
The RANZCP has been advised that some commercial medication suppliers have depleted their supplies of alternate products which were available under section 19A.
For more information regarding availability under the special access scheme, see the Therapeutic Goods Administration’s (TGA) Medicine Shortages Information Initiative.
19 August 2019
Parnate tranylcypromine (as sulphate) 10mg film coated tablet blister pack (AUST R: 174086) is currently unavailable in Australia with supply predicted to be impacted until November 2019.
The Therapeutic Goods Administration (TGA) have approved supply of an unregistered product under section 19A.
The following commercial medication suppliers have been able to arrange limited supplies of alternative products on a temporary basis:
- BNM Group - Tranylcypromine 10mg tablets (Concordia Pharmaceuticals) – see BNM advisory letter [PDF; 221 KB] for further information about the approved product.
- Medsurge - Tranylcypromine sulfate 10mg film coated tablets (Alvogen Inc) – see Medsurge advisory letter [PDF; 298 KB] for further information about the approved product.
These products are not registered in Australia and supply is authorised under an approval granted by the TGA under Section 19A of the Therapeutic Goods Act (1989) until 1 December 2019 for the following indication:
Treatment of symptoms of depressive illness especially where treatment with other types of antidepressants has failed. It is not recommended for use in mild depressive states resulting from temporary situational difficulties.
Further information can be obtained from
For more information and to subscribe to updates, see the TGA’s Medicine Shortages Information Initiative.
For patients taking Parnate, speak to your doctor or pharmacist if you have any questions about your medication.